How accurate is the cerebrospinal fluid seed amplification assay for detecting Lewy body pathology in Alzheimer’s patients?

What we’ve found so far is that all the evidence reviewed supports the idea that this method is highly accurate in identifying Lewy body pathology in individuals already diagnosed with Alzheimer’s. There are no studies in our review that contradict this finding. The test appears to pick up on the presence of these abnormal proteins with very few errors, which could help doctors better understand what’s happening in a patient’s brain during life, rather than only after death.

Lewy body pathology refers to clumps of a protein called alpha-synuclein that can interfere with brain function and are often found alongside the plaques and tangles typical of Alzheimer’s. When both are present, symptoms can be more complex. Knowing whether Lewy bodies are there may help tailor care, even if it doesn’t change the overall diagnosis.

The evidence we’ve reviewed suggests this assay is a promising tool, but it’s still used mostly in research settings. It requires a spinal tap to collect cerebrospinal fluid, which is more involved than a blood draw. We don’t yet know how widely available or practical it is outside specialized clinics.

For now, if you or someone you know has Alzheimer’s and symptoms that seem unusual—like hallucinations or movement problems—this test might offer clearer insight into what’s happening in the brain. But it’s not something most doctors order routinely yet.